Volume 6, Supplement 10SupplementThe Future in Advanced Prostate Cancer: Take Your Partners or Is the Last Dance For Me?David I QuinnTargeted therapyResponse predictionHormonal agentsCytotoxic therapyRadiolabeled nucleotides
Volume 8, Supplement 2Review ArticlesTreatment of Localized Prostate Cancer16th International Prostate Cancer UpdateE David CrawfordBulent AkdumanThis article provides an overview of treatment of localized prostate cancer, which was discussed in detail in the second scientific session of the 16th International Prostate Cancer Update. The role of radical prostatectomy in localized disease was presented by Bob Djavan, MD. Benefits and risks of radical prostatectomy were addressed by Gerald Chodak, MD. Robert E. Donohue, MD, presented the role of radical prostatectomy in Gleason grade 8, 9, and 10 tumors. Impact of positive margins on outcomes after radical prostatectomy was presented by James A. Eastham, MD. E. David Crawford, MD, provided an overview of the role of targeted therapy. Indications and results of brachytherapy were presented by Mack Roach, III, MD. Finally, Michael J. Manyak, MD, described the evolution of radioimmunoscintigraphy and clinical outcomes data. [Rev Urol. 2006;8(suppl 2):S15-S21]Prostate cancerRadical prostatectomyTargeted therapyCryotherapyBrachytherapyLocalized disease
Volume 16, Number 2Review ArticlesFocal Laser Ablation for Localized Prostate Cancer: Principles, Clinical Trials, and Our Initial ExperienceTreatment UpdateHerbert LeporTed LeeNeil MendhirattaDan SperlingFocal therapy of prostate cancer is an evolving treatment strategy that destroys a predefined region of the prostate gland that harbors clinically significant disease. Although long-term oncologic control has yet to be demonstrated, focal therapy is associated with a marked decrease in treatment-related morbidity. Focal laser ablation is an emerging modality that has several advantages, most notably real-time magnetic resonance imaging (MRI) compatibility. This review presents the principles of laser ablation, the role of multiparametric MRI for delineating the site of significant prostate cancer, a summary of published clinical studies, and our initial experience with 23 patients, criteria for selecting candidates for focal prostate ablation, and speculation regarding future directions. [Rev Urol. 2014;16(2):55-66 doi: 10.3909/riu0615] © 2014 MedReviews® LLCProstate cancerFocal therapyTargeted therapyLaser ablation
Volume 18, Number 2Case ReviewTubulocystic Renal Cell Carcinoma: A Great ImitatorTubulocystic renal cell carcinoma (TCRC) is a rare renal tumor. Patients are usually asymptomatic; it is usually detected incidentally, during imaging studies for Bosniak type III and type IV renal cysts. These tumors rarely metastasize. The role of targeted therapy in such rare tumors is still controversial. We report a case of TCRC initially presented as a Bosniak type II renal cyst and was discovered ultimately to be a metastatic disease. This type of presentation might broaden our understanding of this rare disease. [Rev Urol. 2016;18(2):118-121 doi: 10.3909/riu0692] © 2016 MedReviews®, LLCTubulocystic renal cell carcinomaBosniak type II cystTargeted therapy